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Abstract
Background: Systemic Candidia infections are of major concern in neonates, especially in those with risk factors
such as longer use of broad spectrum antibiotics. Recent studies showed that also term babies with underlying
gastrointestinal or urinary tract abnormalities are much more prone to systemic Candida infection. We report a very
rare case of candidiasis caused by Candida kefyr in a term neonate.
Case Presentation: Renal agenesis on the left side was diagnosed antenatally and anal atresia postnatally.
Moreover, a vesico-ureteral-reflux (VUR) grade V was detected by cystography. The first surgical procedure, creating
a protective colostoma, was uneventful. Afterwards our patient developed urosepsis caused by Enterococcus faecalis
and was treated with piperacillin. The child improved initially, but deteriorated again. A further urine analysis
revealed Candida kefyr in a significant number. As antibiotic resistance data about this non-albicans Candida
species are limited, we started liposomal amphotericin B (AMB), but later changed to fluconazole after receiving
the antibiogram. Candiduria persisted and abdominal imaging showed a Candida pyelonephritis. Since high grade
reflux was prevalent we instilled AMB into the child’s bladder as a therapeutic approach. While undergoing surgery
(creating a neo-rectum) a recto-vesical fistula could be shown and subsequently was resected. The child recovered
completely under systemic fluconazole therapy over 3 months.
Conclusions: Candidiasis is still of major concern in neonates with accompanying risk factors. As clinicians are
confronted with an increasing number of non-albicans Candida species, knowledge about these pathogens and
their sensitivities is of major importance.
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Background
Systemic Candida infections in children are of major
concern in preterm infants, neonates with risk factors
and in immunocompromised children [1,2]. Further risk
factors such as use of central venous catheters, longer
use of broad spectrum antibiotics and use of parenteral
nutrition contribute as well [2]. Over the last decade
non-albicans Candida species are emerging as causative
pathogens for systemic Candida infections in children
[3,4]. Here, we report of a candidiasis caused by Can-
dida kefyr in a term neonate.
Case Presentation
After an uneventful birth anal atresia was observed and
a vesico-ureteral-reflux (VUR) grade V was detected by
cystography. Renal agenesis on the left side was already
diagnosed antenatally. The first surgical procedure,
creating a protective colostoma, on day 2 was unevent-
ful. The child was treated with intravenous cefotaxime
for 10 days and was put hereafter on cefixime prophy-
laxis. On day 21 the patient developed an urosepsis
caused by Enterococcus faecalis which was treated with
piperacillin according to the antibiogramm. After initial
improvement the child deteriorated again 10 days after
initiation of antibiotic treatment. Antibiotic therapy was
changed to imipenem, gentamicin and vancomycin. A
lumbar puncture showed normal results, but the urine
analysis revealed significant fungal growth (106 CFU/
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mL). Primary isolation was performed on Candida
Chrom™ Agar (BD) which yielded growth of large
rough pink colonies, resembling Candida krusei. There-
fore systemic antifungal therapy was initiated with lipo-
somal amphotericin B (AMB). Further identification of
the suspected non-albicans Candida species was per-
formed by biochemical identification using the API 20 C
AUX (BioMerieux) biochemical identification panel
which yielded excellent identification (probability >
99.9%, profile number 7220300031). This biochemical
result was confirmed by sequencing of the internal tran-
scribed spacer (ITS) regions using primer pairs ITS 1
and ITS-4 (ITS1: 5-TCCGTAGGTGAACCTGCGG-3,
ITS4: 5-TCCTCCGCTTATTGATATGC-3 and V9D:5-
TTAAGTCCCTGCCCTTTGTA-3 and LS266:5-
GCATTCCCAAACAACTCGACTC-3, respectively) [5].
Both primers span the complete ITS1, 5.8S, and ITS2
regions. A databank search of the amplified sequences
revealed 99% and 100% homology with the ITS region
from Kluyveromyces marxianus which represents the tel-
eomorph form of Candida kefyr. Susceptibility testing
against fluconazole, amphotericin B (AMB), and caspo-
fungin was performed by ellipsometer test ("E-test”) and
showed a minimal inhibitory concentrations (MIC) of
0,25 μg, 0,047 μg, and 0,25 μg, respectively. All tests were
repeated two times with similar results. The inoculum
for susceptibility testing was generally performed by
pooling of 10-20 individual colonies. No macrocolonies
were observed in the inhibition zone of the E-test.
Further subplating and antibiotic susceptibility testing of
individual colonies in order to detect antibiotic suscept-
ibility variants was not performed. Species-specific sus-
ceptibility breakpoints for Candida kefyr have neither
been published by the clinical laboratory institute (CLSI)
nor by the European committee on antimicrobial sus-
ceptibility testing (EUCAST). Therefore we used the
EUCAST breakpoints for Candida albicans for the inter-
pretation of the MICs obtained with the Candida kefyr
isolate. According to these breakpoints the isolate was
susceptible to all three antifungal agents tested. After the
availability of susceptibility data antifungal treatment was
changed to fluconazole. Although the child improved
clinically, a significant candiduria persisted and renal
ultrasound showed persistent signs of Candida pyelone-
phritis (Figure 1). Blood culture results turned out to be
negative. An initial contrast enema did not show a con-
necting fistula between bladder and rectum. But due to
the clinical course a fistula was suspected and surgical
repair of the anorectal atresia was performed. While
undergoing surgery (creating a neo-rectum) a recto-vesi-
cal fistula was found and subsequently was resected.
Since high grade reflux was prevalent in our patient
AMB (1 μg/mL) was successfully instilled into the child’s
bladder twice daily over 7 days. Candida kefyr was
isolated for the last time after 7 days of treatment, after-
wards, all tested urine cultures remained sterile and a
second blood culture remained sterile as well. The child
recovered completely under systemic fluconazole therapy
(8 mg/kg/day) over 3 months.
Discussion
The high burden of systemic Candida infection in chil-
dren with risk factors led to a significant increase in flu-
conazole use over the last decades, which was
accompanied by an increased incidence of non-albicans
Candida species. Interestingly, susceptibility of the main
causative pathogen Candida albicans to fluconazole
remains stable [3,4]. In contrast, a recent study showed
only 82% susceptibility of all isolated non-albicans Can-
dida species to fluconazole [3]. Data regarding suscept-
ibilities of antifungal agents against Candida kefyr are
limited. The isolated Candida kefyr from our patient
was fully sensitive to fluconazole. In a 10.5-year world-
wide surveillance study resistance to fluconazole ranged
from 3.3% in the first 4 study years to 1.7% for all Can-
dida kefyr isolates in the last 3 study-years [4]. So far,
good susceptibilities of AMB against most non-albicans
Candida species were shown, although country specific
differences were observed [4,6,7]. According to a study
from Pfaller et al. the susceptibility of Candida kefyr to
amphotericin B appears to be quite low (4 of 10 isolates
were susceptible at ≤ 1 μg/ml) [8]. A study conducted in
Germany involving mainly adult patients showed an
increased MIC of AMB for 9% of all Candida kefyr iso-
lates [9], whereas a more recent study from Spain
showed no increased MIC of AMB [7].
Figure 1 Renal ultrasound. Hyperechogenic renal parenchyma
due to persistent Candida pyelonephritis and massive pelviectasis.
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Although our patient had recurrent infections due to
Candida kefyr and had clinical symptoms of systemic
disease the pathogen Candida kefyr was only isolated
from urine cultures and not from blood cultures or
other sites. Our patient suffered from grade V reflux,
that may led to an ascending kidney infection. However,
it is reported that amongst clinical signs for systemic
disease isolated candiduria may be the only indication
for candidaemia. Studies confirmed that blood cultures
are 40-75% false negative in patients with candidiasis, as
demonstrated in patients with autopsy proven candidia-
sis [10,11]. In addition to clinical signs of systemic dis-
ease, our patient had renal involvement as well, such as
parenchymal changes on ultrasound. An ascending
infection would be expected to result in isolated pelvica-
lyceal disease, and it is known that haematogenous
spread is the most common route for renal candidiasis
[12]. Therefore, it is conceivable, that patients may have
transient candidaemia that may lead to organ involve-
ment. Nevertheless, it is known that blood cultures are
often no longer positive when renal candidiasis becomes
manifest [13]. As candiduria is regarded as a risk factor
for invasive candidiasis [14] clinicians should be aware
of this, even though blood cultures might remain
negative.
Up to now Candida kefyr is considered as not patho-
genic to healthy individuals, but has been discussed as
an emerging pathogen in patients with risk factors.
Pediatric data are sparse, reporting isolation of Candida
kefyr from 1.8% to 4% of all isolated Candida species
from mainly preterm und low birth weight neonates
[15,16]. In adults Candida kefyr has been reported to
cause systemic Candida infection in patients with neu-
tropenic leukemia [17] and in a woman with underlying
heart disease [18]. Very recently Candida kefyr was
described as a pathogen causing invasive fungal enteritis
in a patient with underlying haematological disease fol-
lowing bone marrow transplantation [19]. Of note, Sen-
did et al. report a twofold detection rate of Candida
kefyr isolates from adult patients in oncohematology
wards compared to patients in other wards (4.8% vs.
1.9%) [20]. Up to now, it is not known why Candida
kefyr is found more often in these patients. Induced
selection of Candida kefyr following antimicrobial ther-
apy or prophylaxis is discussed, as well as factors that
might influence gastrointestinal homeostasis in favour of
Candida kefyr [20]. Furthermore, as Candida kefyr is
commonly found in dairy products, dietary habits might
influence or promote colonization and subsequent infec-
tion in patients as well [21].
Conclusion
As clinicians are confronted with an increasing number
of non-albicans Candida species, knowledge about
these pathogens and their sensitivities is of major
importance. In children with recurrent candiduria sys-
temic infection and organ involvement should be ruled
out, even though blood cultures might remain
negative.
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